Xarelto Expanded Indication May Depend On Containing Worries About Bleeding
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will review J&J/Bayer’s anticoagulant for a claim of reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome. The product has a profoundly stronger database, but the same set of safety concerns, compared to when it was initially approved.
You may also be interested in...
Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
With positive data now in for Xarelto’s ability to treat and prevention recurrence of VTE, Janssen looks to file for a fourth indication for the novel anticoagulant, positioning the drug to crack a promising market that may be under-appreciated.
Xarelto Approval For DVT Bodes Well For Coming Indications
FDA's July 1 approval of Johnson & Johnson's oral anticoagulant comes after a long review process, and in front of some key decision points that will shape the rivaroxaban program's future.